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The N-terminal part of native one-chain tissue plasminogen activator from melanoma cells is not 
homogeneous. The protein chain starts at two different positions, in all probability representing a 
processing difference in the N-terminus. Both ‘long’ L-chains and 3-residue shorter S-chains are present 
in the preparations. In addition, results compatible with a positional Ser/Gly microheterogeneity were 
obtained at a single position (position L-4 which is equal to S-l). The N-terminal tripeptide difference 
seems to be coupled to the possible microheterogeneity: L-chains contain Ser in this position, while S- 
chains appear to contain predominantly Gly. 
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1. INTRODUCTION 
Tissue plasminogen activator has been purified 
from culture medium of a melanoma cell line, 
Bowes [1,2]. It is a one-chain glycosylated 
polypeptide with M, -72000 [l-3], for which a 
527-residue amino acid sequence has been deduced 
from analysis of the corresponding cDNA [4]. A 
shorter cDNA segment has also been cloned [5]. 
On treatment with plasmin, the one-chain ac- 
tivator is cleaved approximately in the middle [2,3] 
to produce 2 disulfide-connected chains (A and B, 
from the N- and C-terminal ends, respectively). 
The B-chain is homologous to the catalytic chains 
of plasmin, thrombin and other serine proteases 
[2,4,5]. Properties of the different activator forms 
are summarized in fig.1, which also explains the 
nomenclature used here. 
from melanoma cell cultures can exhibit two ‘N- 
terminal sequences, differing by the lack of the 
tripeptide HzN-Gly-Ala-Arg- at the start of one 
of the structures. Consequently, the shorter chain 
(S) starts with position 4 of the longer variant (L). 
Preparations apparently exhibiting only S-chains 
have also been reported [4]. Plasmin (apart from 
giving the two-chain cleavage) cleaves off the extra 
N-terminal tripeptide in the L-chain [2], thus 
removing the N-terminal S/L heterogeneity in the 
A-chain. Therefore, the A-chain is always S-type. 
Apart from the one-chain/two-chain variation, 
3 other types of possible variants have been 
reported [2]. First, direct sequence analysis reveal- 
ed that the molecules consist of polypeptides star- 
ting at different positions [2]. Thus, the material 
A second variation is reflected by molar mass 
differences, possibly due to internal carbohydrate 
differences in the A-part, constituting type I and 
type II activator molecules [4,6]. Finally, some 
evidence for positional microheterogeneities has 
been obtained. A Ser/Gly exchange at position S-1 
appeared possible [2], but results on analyses of IS-, 
L- and A-chains were partly conflicting. The 
evidence for the residue exchange is now repeated- 
ly obtained. In addition, the different results on 
the conflicting identity of the residues can be ‘ex- 
plained and seem to correlate with the S/L dif- 
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Fig. 1. Schematic representation of the different forms of tissue plasminogen activator. Four different types of variation 
seem to occur in activator preparations: (a) one-chain forms (L + S-chains) versus two-chain forms (disulfide-linked A 
and B chains, as obtained by cleavage during activation by plasmin); (b) internal differences giving types I and II (with 
different M); (c) processing (at arrows marked L and S) differences (with non-stoichiometric leavages at S) giving L- 
and S-chains (plasmin can also complete cleavage at S apart from cleaving between A- and B-chains); and (d) suggested 
positional differences at L-4. (a,b) relationships are from [2-41; (c,d) results from this study. Positional numbers refer 
to the L-chain (with B-chain numbers taken from [4] after adjustment to the L-chain relationships now reported). 
ference, thus suggesting an apparent association 
between two types of microheterogeneity in the 
activator protein. 
2. MATERIALS AND METHODS 
Tissue plasminogen activator was prepared and 
treated with plasmin as in [2]. For purification of 
the N-terminal CNBr-fragment, native prepara- 
tions were first treated with plasmin, reduced and 
carboxymethylated [2]. The carboxymethylated A- 
and B-chains (40 nmol) were then separated on 
an arginine-Sepharose column (2.5 x 3 cm) equi- 
librated with 0.5 M ammonium bicarbonate and 
O.OlQo Tween 80. The B-chain eluted unretarded, 
while the bound A-chain was eluted with guani- 
dinium hydrochloride (0.6 M). After desalting, the 
carboxymethylated A-chain (25 nmol) was treated 
for 24 h with CNBr (125 mg) in 70% formic acid 
(1 ml). Three fragments were separated on a 1.6 x 
150 cm TSK 55F column (Merck), equilibrated 
with 30% acetic acid, the smallest being the 
N-terminal CNBr-fragment corresponding to posi- 
tions 4-16 of the native L-chain (positions 1-13 of 
the S-chain). 
Total compositions were determined by amino 
acid analysis in a Beckman 121M analyzer after 
acid hydrolysis [2]. Amino acid sequences were 
determined by liquid-phase sequencer degrada- 
tions (Beckman 89OD), using a 0.1 M Quadrol 
peptide program after application in 1% sodium 
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dodecyl sulfate (for one-chain preparations) or in- 
to precycled polybrene [7]. Manual degradations 
were carried out with the dimethylaminoazo- 
benzene isothiocyanate method [8], utilizing by- 
products in the identifications [9]. 
3. RESULTS 
Both native (one-chain) and plasmin-treated 
(two-chain) activator preparations revealed two se- 
quences on direct sequence analysis. The structural 
explanation is given in fig.1, and the supporting 
results of direct sequence analysis are summarized 
in table 1. For the native one-chain activator, two 
residues, corresponding to the L- and S-chains, 
were found in largely similar amounts in all but the 
first position (table 1). The recovery of L- and S- 
chain residues varied somewhat between prepara- 
tions, suggesting L/S ratios of between 1: 3 and 
1: 1 in 5 different preparations studied, including 
separated type I and type II one-chain activators. 
The plasmin-treated preparations also gave 2 se- 
quences, corresponding to the A- and B-chains, 
but the A-chain sequence gave only single results 
(corresponding to the S-type), except for cycle 1, 
where two residues (Ser and Gly) were obtained 
(table 1). The direct sequence analyses therefore 
appear to suggest hat native single-chain prepara- 
tions predominantly consist of protein chains of 
the type Lser_ and sOrY_l, recovered in similar 
amounts. Manual sequence analysis of the N- 
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Table 1 
Results of sequence analyses 
Cycle One-chain preparation 
L-chain S-chain 
Two-chain preparation 
A-chain B-chain 
N-terminal 
CNBr-fragment 
1 Gly (3.6) Gly (3.6)/Ser (trace) Ser (6)/Gly (16) Ile (25) Ser Gly 
2 Ala (4.4) Tyr (5.2) Tyr (19) Lys (18) TYr 
3 Arg (3.0) Gln (1.9) Gln (14) Gly (1% Gln 
4 Ser (2.4) val (5.5) Val (23) GUY (13) Val 
5 Tyr (2.2) Ile (4.2) Ile (21) Leu (23) Ile 
6 Gln (1.9) Cys(Cm) (2.2) Cys(Cm) (6) Phe (18) Cys(Cm) 
One-chain (L + S) preparations (first column) and two-chain (A + B) preparations (second column) analyzed by liquid- 
phase sequencer degradations, and N-terminal CNBr-fragment analyzed by manual dimethylaminoazo benzepe 
isothiocyanate degradations. Results from mixtures are listed ordered into the structure to which they belong, values 
show nmol recovered from the high-performance liquid chromatography identifications (Gly, Ser, Arg, Gln, Cys(Cm) 
normally recovered in lower yield than hydrophobic residues). Nomenclature is given in fig.1 
terminal CNBr-fragment from the A-chain sup- 
ported this conclusion by showing the presence of 
N-terminal Gly and Ser in equal amount. 
Combined, the results reveal that of the 4 
theoretically possible chains that may be derived 
from one processing difference (L/S chains) and 
one apparent positional microheterogeneity 
(Gly/Ser), only two chains seem to exist in larger 
quantity, Lser-4 and SolY-i (cf. fig.l), suggesting an 
association between the two types of 
heterogeneity. 
4. DISCUSSION 
One heterogeneity in the N-terminal region of 
native melanoma cell one-chain tissue plasminogen 
activator is clearly shown (table 1). Hence, protein 
chains of 2 types (L and S) exist, differing by the 
presence or absence of 3 residues. Interestingly, 
another such difference has been noticed in a com- 
pletely different activator [lo]. Relative amounts 
of the present melanoma activator’s L and S chains 
vary but both chains have been detected in 5 dif- 
ferent preparations tudied. The presence of an N- 
terminal heterogeneity in starting position is in 
agreement with another report [2]. However, other 
preparations of the same melanoma cell activator 
have apparently been found to start at only one 
position (present S-type of chain) [4]. This 
variability in starting position may be due to in- 
herited differences between cell cultures or to the 
presence of proteolytic (e.g., plasmin-like) con- 
taminants, cleaving the arginyl bond after residue 
3 of the L-chain. In any event, cell cultures can 
yield different preparations, and a starting posi- 
tion previously deduced [4] need not be 
characteristic for tissue plasminogen activator. 
The other heterogeneity discussed, concerns a 
suggested Gly/Ser exchange at position L-4 
(= S-l). Sequence analysis of the N-terminal 
CNBr-fragment suggests both Gly and Ser in the 
position corresponding to S-l (table l), and direct 
sequence analyses of native activator preparations 
reveal essentially only Gly (in the first cycle cor- 
responding to L-l and S-l) but essentially only Ser 
in the fourth cycle corresponding to L-4 (plus Val 
from S-4, cf. table 1). Similarly, plasmin-treated 
preparations appear to give both Ser and Gly from 
position A-l (plus Ile from B-l). 
The positional heterogeneity is consistent with 
results from one study [2] but was not reported 
from another [4]. Therefore, it is possible, exactly 
as with the processing, that different cultures may 
produce different structures. Of course, the 
discovery of Gly in S-l and A-l but Ser in L-4 can 
reflect a contamination with free Gly. Data are 
also difficult to interpret since all preparations are 
anyway heterogeneous from the L/S heterogeneity 
(also affecting Gly in the first cycle). However, a 
Gly-contamination seems insufficient as explana- 
tion to the results, since not only is Gly detected! in 
cycle 1 of the intact activator (table 1, column 1) 
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but Ser is also consistently recovered in a lower 
amount in this cycle than in cycle 4 of the native 
preparation (table 1, column 1) or in cycle 1 of the 
plasmin-cleaved preparation (table 1, column 2). 
Therefore, if N-terminal Ser is not destroyed and 
a Gly contamination simultaneously acquired in 
the same preparations, the results are difficult to 
explain in the absence of heterogeneity in position 
L4/Sl. It is true that N-terminal Ser may be 
preferentially removed by selective acetyl-group 
blocking during nascent processing [l 11, but a 
coincidence between such a blocking and a Gly- 
contamination also seems unlikely. In conclusion 
therefore, a positional Gly/Ser microheterogeneity 
is the probable explanation to the results obtained. 
The origin of this heterogeneity is unknown. 
However, the presence of a second genetic locus 
seems unlikely [4]. Possibly therefore, the 
heterogeneity may be derived from normal allelic 
variations or from mutational events after separa- 
tion of the Bowes cultures studied. 
Finally, the suggested positional Gly/Ser dif- 
ference appears to correlate with the 3-residue L/S 
shift. Thus, of the 4 structural combinations possi- 
ble from 2 different heterogeneities, only 2 are 
detectable, suggesting an uncommon association 
between 2 types of protein heterogeneity. This pat- 
tern explains the previously conflicting data ob- 
tained on analyses of S-, L- and A-chains [2]. 
Regarding the origin of the association, it may 
be noticed that the activator is synthesized in a 
larger pro-form [4] which is released to the culture 
medium after proteolytic cleavage(s) in the N- 
terminus. Two explanations to the association of 
heterogeneities appear possible. Either, pro-forms 
may differ in additional positions that affect the 
signal, and hence position, for cleavage. Alter- 
natively, the protease responsible for the 
cleavage(s) may prefer Arg-Gly bonds before 
Arg-Ser bonds. Interestingly, both these 
specificities are different from those typical for 
nascent signal peptide cleavages [12]. Instead, the 
Arg-Gly cleavage (which is from a structure 
Arg-Arg-Gly 141) resembles the specificity of hor- 
monal and other pro-form cleavages [4] which 
typically occur after dibasic structures [13]. That 
specificity even appears common enough to be 
reflected as a partly restricted sequence in proteins 
not destined for this cleavage [14]. In any event, 
the two-chain processing by plasmin is obviously 
50 
different from the N-terminal L/S processing, 
since the L/S difference created in the one-chain 
processing is destroyed by plasmin. Independent of 
the processing enzymes, the present results 
establish complicated patterns in the activator N- 
terminal region, and suggest associations between 
different events. 
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